Our present study therefore identified induction of TOPK-survivin as a novel mechanism that contributed to cancer cells resistant to ABT-737 and targeting this axis may represent a novel approach to augment therapeutic efficacy of ABT-737. This evidence concerns the gene BIRC5 and cancer.